1 Min Read
May 30 (Reuters) - Abeona Therapeutics Inc:
* Abeona Therapeutics receives rare pediatric disease designation for eb-101 gene therapy product for patients with Epidermolysis Bullosa Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.